Member Info for MickTKipper

IGR International Greetings. Another Broker Note International Greetings PLC IGR Beaufort Securities Speculative Buy 180.50 179.50 - - Reiterates Speculative!!!!!!!!! didnt look that way to me on the RNS yesterday.

TRI Trifast Cracking update, should get a run up to results now....... <b>Accordingly, the Board expects the results for the year ended 31 March 2016 to be towards the upper end of market expectations.</b> http://www.investegate.co.uk/trifast-plc--tri-/rns/trading-update-and-notice-of-results/201604190700095714V/

IGR Bullish article, must have come out late.......not sure how much stock is on loan??. <b>Will International Greetings plc Short Squeeze Soon? The Stock Just Gapped Up</b> APRIL 18, 2016 BY STAFF WRITER IN STOCK NEWS · The stock of International Greetings plc (LON:IGR) gapped up by GBX 8.5 today and has GBX 310.54 target or 73.00% above today’s GBX 179.50 share price. The 5 months technical chart setup indicates low risk for the GBX 106.36 million company. The gap was reported on Apr, 19 by Barchart.com. If the GBX 310.54 price target is reached, the company will be worth GBX 77.64 million more. Gaps up are useful for using as a support level and to some extent as a tradeable event. If investors already hold the stock and experience a price gap up, then its usually a good idea to hold the stock for a stronger up move. Back-tests of these patterns indicate that two-thirds of the times the stock performance improves after the gap. The area gaps close 89% of the time, the breakaway gaps, 2%, the continuation gaps 4% and the exhaustion gaps 61%. The stock increased 15.06% or GBX 23.5 on April 18, hitting GBX 179.5. About 183,337 shares traded hands or 752.29% up from the average. International Greetings plc (LON:IGR) has risen 23.79% since September 17, 2015 and is uptrending. It has outperformed by 17.00% the S&P500.

EPS here one heck of an uplift. <b><u>Broker Edison;</b></u> <b><i>The year-end trading update indicates that International greetings (IGR) ended FY16 strongly in all its geographic regions, with good momentum into the new financial year. FY16 earnings per share will be at least 13.0p (Edison forecast: 12.1p). Cash performance was also well ahead, with deleveraging comfortably outperforming our modelled outcome, which showed an end-March net debt figure of £26m. The full year dividend is to be recommended at 2.5p (our forecast: 2.0p). FY16 numbers and FY17 estimates will be revised up on publication of the full year numbers at end June, underlining the strong value in the shares at current levels.</b></i>

International Greetings' (IGR) financial performance in the year ended 31 March was ahead of expectations, resulting in a further year of double digit earnings per share growth. The shares were up 11.79% at 174.4p. http://www.iii.co.uk/stockmarketwire/310187/ftse-100-decisively-lower-oil-mining-and-financial-stocks

IGR International Greetings. SP moving up after the company reported this morning financial growth beyond expectations in many areas of the Business. Looking forward to Broker UPGRADES. http://content.screencast.com/users/marketsniper/folders/Default/media/340869cf-3bae-49f0-92d6-012a905cf3ea/igr%201.jpg <b><u>Company</b></u> International Greetings Plc engages in the designing, manufacturing and distribution of gift packaging and greetings, stationery and creative play products.The company products include licensing, gift wrapping, crackers, cards, stationery and activity, gifts and bags. <b><u>Valuation 2016e 2017e</b></u> P/E ratio (Price / EPS) 12,9x 12,1x Capitalization / Revenue 0,40x 0,39x EV / Revenue 0,51x 0,48x EV / EBITDA 6,89x 6,33x Yield (DPS / Price) 1,28% 1,92% Price to book (Price / BVPS) - -

Financial performance is ahead of expectations' in ALL areas...... http://www.investegate.co.uk/intnl-greetings-plc--igr-/rns/trading-update/201604180700074162V/

Scapa Group plc 27.1% Potential Upside Indicated by Berenberg Posted by: Katherine Hargreaves 15th April 2016 Scapa Group plc using EPIC/TICKER code LON:SCPA has had its stock rating noted as ‘Retains’ with the recommendation being set at ‘BUY’ this morning by analysts at Berenberg. Scapa Group plc are listed in the Basic Materials sector within AIM. Berenberg have set their target price at 300 GBX on its stock. This is indicating the analyst believes there is a potential upside of 27.1% from the opening price of 236 GBX. Over the last 30 and 90 trading days the company share price has increased 31.2933 points and increased 49 points respectively. Scapa Group plc LON:SCPA has a 50 day moving average of 204.10 GBX and a 200 day moving average of 202.42 GBX. The 1 year high share price is 245 GBX while the 52 week low is 156.73 GBX. There are currently 150,942,761 shares in issue with the average daily volume traded being 361,839. Market capitalisation for LON:SCPA is £363,394,697 GBP.

Lavendon Group plc 100.7% Potential Upside Indicated by Peel Hunt Posted by: Katherine Hargreaves 14th April 2016 Lavendon Group plc using EPIC/TICKER code LON:LVD had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘BUY’ today by analysts at Peel Hunt. Lavendon Group plc are listed in the Industrials sector within UK Main Market. Peel Hunt have set a target price of 275 GBX on its stock. This now indicates the analyst believes there is a possible upside of 100.7% from the opening price of 137 GBX. Over the last 30 and 90 trading days the company share price has decreased 9.25 points and increased 5 points respectively. Lavendon Group plc LON:LVD has a 50 day moving average of 141.93 GBX and a 200 day moving average of 154.26 GBX. The 52 week high share price is 211.5 GBX while the 52 week low for the share price is 120.75 GBX. There are currently 169,711,599 shares in issue with the average daily volume traded being 307,235. Market capitalisation for LON:LVD is £235,899,123 GBP.

SCPA SCAPA Group PLC Berenberg note this morning was in fact an upgrade in the SP, details below.... 08:10 Broker Forecast - Berenberg issues a broker note on Scapa Group PLC Berenberg today reaffirms its buy investment rating on Scapa Group PLC (LON:SCPA) and raised its price target to 300p (from 260p). Story provided by StockMarketWire.com

SCPA SCAPA Group A number of Broker updates out yesterday, IMO they are holding back while the results next month before revising earnings upwards.......... Numis Securities Ltd 14-04-16 ADD 20.60 10.60 2.10 23.30 12.00 2.60 Cantor Fitzgerald Europe 14-04-16 HOLD 19.80 9.70 2.00 22.20 10.90 2.30 Arden Partners 14-04-16 ADD 19.40 9.88 2.00 22.40 11.41 2.60 N+1 Singer 14-04-16 CORP 20.60 10.20 2.00 21.68 10.60 2.30

SCPA Scapa Group broker Buy out...... Scapa Group PLC SCPA Berenberg Buy 242.75 242.75 260.00 300.00 Retains SP Target 300p

CEO comment....... Heejae Chae, CEO commented: "We have delivered another set of strong results which are ahead of expectations as we execute our strategies for Healthcare and Industrial. Notwithstanding challenging global market conditions, we remain confident of achieving further progress through organic growth and acquisitions." Scapa expects to report its full year results on 24 May 2016.

SCPA Scapa Group fantastic results...... http://www.investegate.co.uk/scapa-group-plc--scpa-/rns/trading-statement/201604140700071326V/ "Group revenue is ahead of last year and Group trading profits* and margins are both ahead of last year and expectations". http://uk.advfn.com/p.php?pid=legacydaily&epic=L^SCPA&type=4&size=3&period=4&ind_type1=1&ind1_1=&ind2_1=&ind_type2=8&ind1_2=&ind2_2=&ind_type3=4&ind1_3=14&ind2_3=&olx_1=3&ma_type1=3&o_1maday1=25&o_2maday1=&o_colour1=1&olx_2=3&ma_type2=3&o_1maday2=50&o_2maday2=&o_colour2=2&olx_3=3&ma_type3=3&o_1maday3=160&o_2maday3=&o_colour3=3&scheme=&delay_indices=DELAYED_INDICES

CPR Carpetright PLC Positive divergence now showing on the chart. Looks like 500p will be the first major SP target. http://content.screencast.com/users/marketsniper/folders/Default/media/21d4de88-439c-4f11-a855-f9fdd538c2e8/cpr%203.jpg <b><u>Company</u></b> Carpetright Plc engages in retailing carpets and floor coverings.It sells floor coverings, carpets, vinyls, rugs and laminates together with associated accessories. <b><u>Valuation 2016e 2017e</u></b> P/E ratio (Price / EPS) 18,1x 14,0x Capitalization / Revenue 0,51x 0,51x EV / Revenue 0,51x 0,48x EV / EBITDA 7,28x 6,05x Yield (DPS / Price) 0,17% 2,34% Price to book (Price / BVPS) 3,17x 2,74x

HIK Hikma Pharma Goes to the top of my red hot watch list after results today. <a href='http://www.investegate.co.uk/hikma-pharmaceutical--hik-/rns/final-results/201603160700132201S/' target='window'>http://www.investegate.co.uk/hikma-pharmaceutical--hik-/rns/final-results/201603160700132201S/</a> http://uk.advfn.com/p.php?pid=legacydaily&epic=L^HIK&type=4&size=3&period=4&ind_type1=1&ind1_1=&ind2_1=&ind_type2=2&ind1_2=12&ind2_2=&olx_1=3&ma_type1=3&o_1maday1=25&o_2maday1=&o_colour1=1&olx_2=3&ma_type2=3&o_1maday2=50&o_2maday2=&o_colour2=2&olx_3=3&ma_type3=3&o_1maday3=160&o_2maday3=&o_colour3=3&scheme=&delay_indices=DELAYED_INDICES <b><u>Broker Cantor</u></b> <b><i>Revenue performance largely in line – Having provided a trading statement in November last year which detailed revenue and margin expectations, an inline performance in terms of todays reported numbers is hardly surprising. Injectables revenues of $710 (+3% CER%), was slightly ahead of our expectations of $699m with an adjusted operating margin of 44%. Revenue in the Branded business, driven by a recovery in Algeria, strong growth in Egypt and good demand in Saudi Arabia as well as other gulf states, was $570m (+13% CER) versus our forecast of $579m accompanies by a modest improvement in the adjusted operating margin of 3.9% (at CER). Lastly Generics delivered revenue of $151m (-30%) compared to our forecast of $151m at a respectable adjusted operating margin of 30.5%, albeit down from the heady supranormal margins this division has enjoyed over the past couple of years. Overall EPSA of 143.7c (-5%) is ahead of our forecast of $1.28 and consensus of 1.34 helped by a better than expected injectables margin. · Guidance for 2016 – Hikma has provided revenue guidance of $2.0-$2.1bn which compares to our forecast of $2.043bn and consensus of $2.12bn. Guidance for the key injectables division suggests growth of mid to high single digits compared to our forecast of double digit growth although the forecast of a 36% adjusted operating margin is ahead of our forecast of 32%. The combined generics business is expected to deliver sales in the range of $640m to $670m which is ahead of our forecast of $614m suggesting that the mix may favour the traditional generics business over Injectables compared to our initial expectation. Elsewhere the Branded business is guided to perform in line with historical trends. · Generic powerhouse – Mainly through a process of organic growth and timely acquisitions Hikma has grown its injectables and non-injectables generic businesses. The injectables business in particular has delivered stunning growth as it has sought to satisfy the demand for products which have suffered from acute shortages in the US. As a consequence, the division has delivered supra-normal prof

After 9 to 12 months in and out of shorting CRP Carpetright, ive decided to go long and am building a position. It looks derd cheap now and ticks all the right value boxes for growth over the next few years. Heres the Motley fool yesterday summing it up...... (sold WPP for a small profit for my one in one out current policy) Meanwhile, shares in Carpetright (LSE: CRP) are up by around 7% today despite no significant news having been released by the company. Despite this rise, its shares are still down by 29% since the turn of the year, but over the medium term they could easily recover lost ground. <b>A key reason for this is the company’s upbeat earnings forecasts. In the current financial year, Carpetright is expected to increase its bottom line by 23%, with further growth of 30% next year and 23% in the following year being pencilled in. This means that its net profit could be as much as 97% higher within the space of three years, which has the potential to act as a positive catalyst on its share price.</b> And while there are uncertainties surrounding the performance of the UK and European economies, Carpetright’s price to earnings growth (PEG) ratio of 0.5 indicates that there is a sufficiently wide margin of safety on offer to merit purchase right now. http://content.screencast.com/users/marketsniper/folders/Default/media/a4d5a08c-b46e-4730-a4a9-47c7d7496109/cpr%202.jpg

Date Broker Rec. Price Old target price New target price Notes 08 Mar 16 Cantor Fitzgerald Buy 1,404.00 1,650.00 1,650.00 Reiterates 04 Mar 16 Investec Buy 1,404.00 1,850.00 1,850.00 Reiterates 25 Feb 16 Berenberg Buy 1,404.00 1,800.00 1,750.00 Reiterates 22 Feb 16 Peel Hunt Buy 1,404.00 1,800.00 1,800.00 Reiterates 18 Jan 16 RBC Capital Markets Outperform 1,404.00 - - Reiterates 15 Jan 16 Liberum Capital Hold 1,404.00 1,500.00 1,500.00 Reiterates 14 Jan 16 Canaccord Genuity Buy 1,404.00 1,847.00 1,847.00 Retains 14 Jan 16 Investec Buy 1,404.00 1,850.00 1,850.00 Reiterates

SGP Super Group looking frisky.............. http://content.screencast.com/users/marketsniper/folders/Default/media/9a637ce9-a01b-480c-9657-0255637ab4b0/sgp%204.jpg &lt;b&gt;&lt;u&gt;Company&lt;/u&gt;&lt;/b&gt; SuperGroup Plc designs and sells clothing and accessories for men and women through multiple routes to market, including retail, wholesale and online.It operates through the Retail and Wholesale segments. &lt;b&gt;&lt;u&gt;Valuation 2016e 2017e&lt;/u&gt;&lt;/b&gt; P/E ratio (Price / EPS) 20,6x 16,8x Capitalization / Revenue 1,96x 1,75x EV / Revenue 1,85x 1,55x EV / EBITDA 10,2x 8,34x Yield (DPS / Price) 1,49% 1,80% Price to book (Price / BVPS) - -

SGP Super Group looking frisky.............. http://content.screencast.com/users/marketsniper/folders/Default/media/9a637ce9-a01b-480c-9657-0255637ab4b0/sgp%204.jpg <b><u>Company</u></b> SuperGroup Plc designs and sells clothing and accessories for men and women through multiple routes to market, including retail, wholesale and online.It operates through the Retail and Wholesale segments. <b><u>Valuation 2016e 2017e</u></b> P/E ratio (Price / EPS) 20,6x 16,8x Capitalization / Revenue 1,96x 1,75x EV / Revenue 1,85x 1,55x EV / EBITDA 10,2x 8,34x Yield (DPS / Price) 1,49% 1,80% Price to book (Price / BVPS) - -